IMAC HOLDINGS INC (BACK) Stock Price & Overview

NASDAQ:BACKUS44967K3023

Current stock price

0.2 USD
-0.22 (-52.65%)
At close:
0.1269 USD
-0.07 (-36.55%)
After Hours:

The current stock price of BACK is 0.2 USD. Today BACK is down by -52.65%. In the past month the price decreased by -67.02%. In the past year, price decreased by -93.46%.

BACK Key Statistics

52-Week Range0.1413 - 7.75
Current BACK stock price positioned within its 52-week range.
1-Month Range0.1413 - 0.63
Current BACK stock price positioned within its 1-month range.
Market Cap
674K
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-4.76
Dividend Yield
N/A

BACK Stock Performance

Today
-52.65%
1 Week
-54.26%
1 Month
-67.02%
3 Months
-84.62%
Longer-term
6 Months -82.30%
1 Year -93.46%
2 Years -95.34%
3 Years N/A
5 Years N/A
10 Years N/A

BACK Stock Chart

IMAC HOLDINGS INC / BACK Daily stock chart

BACK Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to BACK. When comparing the yearly performance of all stocks, BACK is a bad performer in the overall market: 99.24% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BACK Earnings

On January 17, 2025 BACK reported an EPS of -1.38 and a revenue of 56.00K. The company missed EPS expectations (-55.51% surprise).

Next Earnings DateApr 14, 2025
Last Earnings DateJan 17, 2025
PeriodQ3 / 2024
EPS Reported-$1.38
Revenue Reported56K
EPS Surprise -55.51%
Revenue Surprise %

BACK Forecast & Estimates

7 analysts have analysed BACK and the average price target is 8.41 USD. This implies a price increase of 4107.5% is expected in the next year compared to the current price of 0.2.

For the next year, analysts expect an EPS growth of 69.42% and a revenue growth -100% for BACK


Analysts
Analysts82.86
Price Target8.41 (4105%)
EPS Next Y69.42%
Revenue Next Year-100%

BACK Groups

Sector & Classification

Index Membership

BACK Financial Highlights

Over the last trailing twelve months BACK reported a non-GAAP Earnings per Share(EPS) of -4.76. The EPS increased by 66.07% compared to the year before.


Income Statements
Revenue(TTM)72.10K
Net Income(TTM)-14.57M
Industry RankSector Rank
PM (TTM) N/A
ROA -993.1%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%47.53%
Sales Q2Q%-96.42%
EPS 1Y (TTM)66.07%
Revenue 1Y (TTM)-99.15%

BACK Ownership

Ownership
Inst Owners1.61%
Shares3.37M
Float3.11M
Ins Owners3.33%
Short Float %0.25%
Short Ratio0

About BACK

Company Profile

BACK logo image IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 2 full-time employees. The company went IPO on 2019-02-13. The firm is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The firm is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The firm is also engaged in providing the precision medicine business. The firm's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.

Company Info

IPO: 2019-02-13

IMAC HOLDINGS INC

3401 Mallory Lane, Suite 100

Franklin TENNESSEE US

Employees: 3

BACK Company Website

BACK Investor Relations

Phone: 18442664622

IMAC HOLDINGS INC / BACK FAQ

Can you describe the business of IMAC HOLDINGS INC?

IMAC Holdings, Inc. provides medical services through integrated medicine and chiropractic regeneration centers. The company is headquartered in Franklin, Tennessee and currently employs 2 full-time employees. The company went IPO on 2019-02-13. The firm is focused on innovative medical advancements and care in the oncology, neurological, and orthopedic medical specialties. The firm is focused on providing natural, non-opioid solutions to pain as consumers demand conservative treatments for an aging population. Its Investigational New Drug division conducted a clinical trial for its investigational compound utilizing umbilical cord-derived allogenic mesenchymal stem cells for the treatment of bradykinesia due to Parkinson’s disease. The firm is also engaged in providing the precision medicine business. The firm's technology, through its patented phosphoprotein and protein biomarker platform and lab developed tests (LDTs), targets multiple areas of oncology and drug development. Its LDTs are utilized by oncologists across the United States to assist in making the targeted treatment plan for their patients with advanced breast cancer.


What is the current price of BACK stock?

The current stock price of BACK is 0.2 USD. The price decreased by -52.65% in the last trading session.


Does BACK stock pay dividends?

BACK does not pay a dividend.


How is the ChartMill rating for IMAC HOLDINGS INC?

BACK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.


Where is IMAC HOLDINGS INC (BACK) stock traded?

BACK stock is listed on the Nasdaq exchange.


How is the valuation of IMAC HOLDINGS INC (BACK) based on its PE ratio?

IMAC HOLDINGS INC (BACK) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.76).


What is the employee count for BACK stock?

IMAC HOLDINGS INC (BACK) currently has 3 employees.